ELC Group Appoints Head of Regulatory Affairs for Russia and CIS
News Jul 29, 2014
ELC Group has announced the appointment of Inna Demidova as a Senior Regulatory Affairs Expert for Russia and the Commonwealth of Independent States (CIS).
Previously with Ferring Pharmaceuticals as Regulatory Affairs Manager, Inna Demidova is an expert on both the Russian and CIS regulatory environment and clinical trials organizations, having managed numerous teams through rigorous registration, QA and medical activities. Inna Demidova will also be tasked with heading ELC Group’s planned Moscow office, due to open later in 2014.
The establishment of a regional base in Russia comes off the back of a record year of growth and revenue performance for ELC Group, with office openings in Brazil and China set to follow soon.
Commenting on the appointment, ELC Group’s CEO Marco Rubenstein said: “We are very pleased to welcome Inna to the ELC Group team. Her knowledge and experience of the Russian and CIS territories is extremely impressive and we look forward to rapidly expanding our presence under her expert guidance.”
Inna Demidova added: “I am very excited to be joining ELC Group as Head of Regulatory Affairs for Russia and CIS, and to bringing ELC Group’s market-leading services to these crucial markets.”
Inna Demidova studied Pharmacology at Medical State University in Almaty, Kazakhstan, before later receiving a Bachelor of Science from Portland Business College.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018